ID: ALA177853

Max Phase: Preclinical

Molecular Formula: C16H17NO6

Molecular Weight: 319.31

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)c1cccc(NC(=O)C2C(C(=O)O)[C@@H]3CC[C@H]2O3)c1

Standard InChI:  InChI=1S/C16H17NO6/c1-22-16(21)8-3-2-4-9(7-8)17-14(18)12-10-5-6-11(23-10)13(12)15(19)20/h2-4,7,10-13H,5-6H2,1H3,(H,17,18)(H,19,20)/t10-,11+,12?,13?/m1/s1

Standard InChI Key:  QQYOGYLHZFMAPH-IALDZJHCSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 319.31

Molecular Weight (Monoisotopic): 319.1056

AlogP: 1.29

#Rotatable Bonds: 4

Polar Surface Area: 101.93

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.58

CX Basic pKa:

CX LogP: 1.25

CX LogD: -2.10

Aromatic Rings: 1

Heavy Atoms: 23

QED Weighted: 0.81

Np Likeness Score: -0.49

References

1. Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A..  (2004)  Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.,  14  (8): [PMID:15050639] [10.1016/j.bmcl.2004.01.093]

Source

Source(1):

• Scientific Literature